Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 10/20 | 0.60 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PAH | P00439 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9663134 | 0.93 | HPRT1 (0.55) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL711245 | 0.90 | HPRT1 (0.55) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL146837 | 0.89 | HPRT1 (0.58) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL11218913 | 0.88 | HPRT1 (0.50) | HPRT1 | |
| SCHEMBL7192798 | 0.88 | HPRT1 (0.57) | HPRT1NOS1USP2CASP7HSD17B10 | |
| Water SCHEMBL10414024 | 0.88 | HPRT1 (0.57) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL7197096 | 0.88 | HPRT1 (0.57) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL7142937 | 0.87 | HPRT1 (0.64) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL9116476 | 0.87 | HPRT1 (0.54) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL10916964 | 0.86 | HPRT1 (0.56) | HPRT1NOS1USP2CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | claimed |
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | claimed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | claimed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | METABASIS THERAPEUTICS, INC. | 2008-05-29 | — | — | US | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | claimed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
| EP-0055239-B1 | NOVEL DERIVATIVES OF GUANINE | Astra Läkemedel Aktiebolag (SE) | 1986-07-16 | — | — | EP | claimed |
| US-4495190-A | VIRICIDES; ANTITUMOR AND ANTICARCINOGENIC AGENTS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1985-01-22 | — | — | US | claimed |
| WO-1982002202-A1 | NOVEL DERIVATIVES OF GUANINE | ASTRA LAEKEMEDEL AB (SE) | 1982-07-08 | — | — | WO | claimed |
| EP-0055239-A1 | Novel derivatives of guanine | Astra Läkemedel Aktiebolag (SE) | 1982-06-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | PYGL, ALPI, SLC10A1 | HPRT1 227/4885NOS1 3670/4885USP2 4282/4885 |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | HPRT1 227/4885NOS1 3670/4885USP2 4282/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | HPRT1 227/4885NOS1 3670/4885USP2 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.